Healthcare, ECM

Bryan, Garnier & Co acts as Sole Financial Advisor on Median Technologies’ EUR 10 million Bridge Financing

Median Technologies is a French-based, commercial-stage innovative medical imaging expert deploying proprietary Artificial Intelligence, computer vision, and signal processing technologies to provide solutions in drug development and patient care through early diagnosis.

These efforts have shaped the company into two synergistic business units, each providing cutting-edge imaging solutions:

The first, iCRO offers medical image analysis and services for clinical trials. The platform has been evolving since its launch, fine-tuning AI features to optimize the use of images and ease the drug development process. Customers include CROs, biotechs, and pharma companies running phase I-III oncology trials.

The second unit, eyonis is a ‘software as medical devices (SaMD)’ platform aiming to revolutionize medical imaging analysis in routine radiology by offering real-time diagnostics, risk stratification, and disease outcome prediction. Currently at pivotal trial stage in Lung Cancer Screening, Median’s ambition is to identify advanced high-quality biomarkers in medical images to enable the early diagnosis of solid cancers and metabolic diseases in a non-invasive fashion.

Bryan, Garnier & Co acts as Sole Financial Advisor on Median Technologies EUR 10m Bridge Financing from Iris Capital Investment

This EUR 10m financing, with EUR 4m available immediately, is part of a total package of up to EUR 47.5m, which includes a EUR 37.5m loan from the European Investment Bank, currently in the final authorisation stage.

The funds will support the completion of pivotal milestones for Eyonis, including the RELIVE pivotal study results expected in Q1 2025, as well as regulatory filings for FDA approval and CE marking anticipated in Q2 2025. The commercial launch remains on track for Q4 2025.

Thanks to the current financing solution, Median’s cash runway is secured through Q4 2025.

This is the second consecutive capital raise that Bryan Garnier has led for Median Technologies, following its EUR 21.6m follow-on offering and convertible bond issuance in July 2023, as well as another successful transaction for the Bryan Garnier Healthcare Capital Markets Franchise.

Based in France and listed on the Euronext Growth market, Median Technologies is a leader in innovative imaging services and Software as Medical Devices (SaMD). The company uses advanced AI to improve early cancer diagnosis and treatment. With additional offices in the U.S. and China, Median offers iCRO, a service for medical image analysis and management in oncology trials, and eyonis™, an AI/ML-powered suite of software tools. Median helps biopharmaceutical companies and clinicians improve patient care and accelerate the development of new therapies.